1 recruiting, 1 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Long QT Syndrome: new trials by email Literature Review of Long QT Syndrome trials Research Report on Long QT Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) baseline lead-in, THRV-1268 - Long QT Syndrome (LQTS) 2 | Phase 2 / Phase 3 | Recruiting | Thryv Therapeutics, Inc. | 84 | 2026-03-07 | 2026-09-21 |
| Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 Eleclazine, Eleclazine placebo - Long QT Syndrome Type 3 | Phase 3 | Terminated | Gilead Sciences | 41 | 2014-12-17 | 2018-01-12 |
Death, Sudden, Cardiac (1) · Long QT syndrome type 3 (1)
Arrhythmias, Cardiac (2) · Cardiac Conduction System Disease (2) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Heart Defects, Congenital (2) · Heart Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Death (1) · Death, Sudden (1) · Heart Arrest (1)
eleclazine (1)
Gilead Sciences (1) · Thryv Therapeutics, Inc. (1)
United States (2) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
2014 (1)